RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Applied Therapeutics Stock

Applied Therapeutics ROA 2024

Applied Therapeutics ROA

-2.18

Ticker

APLT

ISIN

US03828A1016

WKN

A2PHHB

In 2024, Applied Therapeutics's return on assets (ROA) was -2.18, a 1.65% increase from the -2.15 ROA in the previous year.

Applied Therapeutics Aktienanalyse

What does Applied Therapeutics do?

Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for chronic and specific serious diseases. The company was founded in 2016 by Shoshana Shendelman, who is also the CEO of the company. Applied Therapeutics is headquartered in New York City and currently employs over 50 employees. The business model of Applied Therapeutics is designed to address gaps in current medical care and develop novel therapies that do not yet exist. The company invests heavily in research and development to find new drugs and therapies that are more effective and safer than existing treatment methods. Applied Therapeutics has focused on developing drugs that can be used in the areas of neurological and cardiovascular diseases, as well as metabolic diseases. The main products currently under development aim to treat metabolic diseases such as diabetic neuropathy and mucopolysaccharidosis (MPS). The company has a broad portfolio of technologies, including the targeted protein degrader platform, which aims to degrade critical proteins that play a role in certain diseases. Applied Therapeutics also uses genomics to gain a deeper understanding of the underlying causes of diseases. By identifying targets for new drugs and therapies, the company also uses AI algorithms to select promising candidates for clinical trials. Applied Therapeutics' particular expertise lies in the research of molecules that play a key role in regulating carbohydrate metabolism and energy production in the body. Applied Therapeutics' medications aim to selectively regulate these critical molecules and thus combat various diseases. The first product from Applied Therapeutics is AT-001, a medication for the treatment of diabetic neuropathies. A phase II study has shown that AT-001 provides a significant improvement in neuropathic pain and sensitivity. The medication is currently being tested in a phase III clinical trial. Another promising class of drugs from Applied Therapeutics is the SGLT2 inhibitor, which targets carbohydrate metabolism and thus covers a wide range of diseases, from diabetes to cardiovascular diseases. Applied Therapeutics has also signed a license agreement with the University of Minnesota for the development of medications for the treatment of MPS I. In this collaboration, the company brings its expertise in molecules regulating carbohydrate and energy metabolism to develop a new treatment for MPS patients. It is important to mention that Applied Therapeutics' drugs are still in development and are in various stages of clinical trials. After completing the clinical trials and potential FDA approval, the products must also be brought to market, which can pose additional challenges. Overall, Applied Therapeutics has focused on developing therapies for chronic and serious diseases. The company has a broad portfolio of technologies aimed at combating the underlying causes of diseases. With AT-001 already on the market, the company has brought a promising medication to market, and additional products are in development. Whether the company will meet its ambitious goals remains to be seen, but there is no doubt that it operates in an exciting area with great potential. Applied Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Applied Therapeutics's Return on Assets (ROA)

Applied Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Applied Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Applied Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Applied Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Applied Therapeutics stock

What is the Return on Assets (ROA) of Applied Therapeutics this year?

The Return on Assets (ROA) of Applied Therapeutics is -2.18 undefined this year.

What was the ROA of Applied Therapeutics compared to the previous year?

The ROA of Applied Therapeutics has increased by 1.65% compared to the previous year.

What consequences do high ROA have for investors of Applied Therapeutics?

A high ROA is advantageous for investors of Applied Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Applied Therapeutics?

A low ROA can be unfavorable for investors of Applied Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Applied Therapeutics affect the company?

An increase in ROA of Applied Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Applied Therapeutics impact the company?

A reduction in the ROA of Applied Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Applied Therapeutics?

Some factors that can influence the ROA of Applied Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Applied Therapeutics important for investors?

The ROA of Applied Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Applied Therapeutics take to improve ROA?

To improve ROA, Applied Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Applied Therapeutics pay?

Over the past 12 months, Applied Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Applied Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Applied Therapeutics?

The current dividend yield of Applied Therapeutics is .

When does Applied Therapeutics pay dividends?

Applied Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Applied Therapeutics?

Applied Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Applied Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Applied Therapeutics located?

Applied Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Applied Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Applied Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Applied Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Applied Therapeutics in the year 2023?

In the year 2023, Applied Therapeutics distributed 0 USD as dividends.

In which currency does Applied Therapeutics pay out the dividend?

The dividends of Applied Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Applied Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Applied Therapeutics

Our stock analysis for Applied Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.